Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma

CHINESE CLINICAL ONCOLOGY(2023)

引用 0|浏览2
暂无评分
关键词
Extranodal natural killer/T-cell lymphoma (ENKTL),anti-PD-L1 antibody,sugemalimab
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要